# The Efficacy and Safety of Protoxin in Subjects With Moderate to Severe Glabellar Lines

> **NCT06124794** · PHASE3 · COMPLETED · sponsor: **Protox Inc.** · enrollment: 155 (actual)

## Conditions studied

- Glabellar Frown Lines

## Interventions

- **BIOLOGICAL:** PROTOXIN

## Key facts

- **NCT ID:** NCT06124794
- **Lead sponsor:** Protox Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-12-18
- **Primary completion:** 2024-02-26
- **Final completion:** 2024-06-14
- **Target enrollment:** 155 (ACTUAL)
- **Last updated:** 2024-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06124794

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06124794, "The Efficacy and Safety of Protoxin in Subjects With Moderate to Severe Glabellar Lines". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06124794. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*